RXI-109

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRXI-109
Drug Alias NameRXI-109
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionConnective tissue growth factor inhibitorsRNA interference
TargetsConnective tissue growth factor
Therapy Area/IndicationsCicatrix, HypertrophicCicatrixKeloid +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesHondurasDominican Republic
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRxi Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRxi Pharmaceuticals Corp
Active IndicationsN/A
Inactive IndicationsCicatrix, HypertrophicCicatrixKeloid +[5] 

Other Information

ATC CodeN/A
Related LinksN/A